New Webinar: Cyclic Peptides Synthesis for Drug Discovery

You are here:

Charnwood Discovery and Gyros Protein Technologies have teamed up to produce a live webinar. Principal Scientist, Dr James Krupa will be using his expertise to explore the complexities of cyclic peptide synthesis. 

Click the button below to register for the webinar on the 21 March at 3 pm (GMT).  

Cyclic Peptide Synthesis for Drug Discovery: Uses, Benefits and Challenges

In 2023, peptide-based drugs continued to gain prominence. Three out of six new peptide drug approvals were for cyclic peptides due to their favorable drug properties, such as cell permeability, proteolytic stability and binding kinetics. Cyclic peptides, however, often result in challenging projects due to the difficulty of synthesis or time constraints.

This webinar focuses on the recent advances in peptide drug development. Specifically, focusing on cyclic peptides and the challenges involved in their manufacturing, handling and applications from a CRO’s perspective.

Experts will explore the nuances of cyclic peptide synthesis and how a Contract Research Organisation (CRO) leverages state-of-the-art technology to enhance its capabilities to meet complex project requirements. Attendees will learn about the synthesis and cyclization of peptides, potential issues with ring strain and what to look for when working with unstable cyclic peptides, as well as approaches to understanding the structure–activity relationship (SAR) of a cyclic peptide and some issues in drug discovery. This session is ideal for anyone interested in cyclic peptide synthesis and its role in drug discovery.

The webinar will take place on Thursday 21 March at 3 pm (GMT)/ 11 am (EDT). Register for this webinar to understand the challenges and strategies for synthesizing cyclic peptides and understand its role in drug discovery.

About the Speaker

Dr James Krupa is a Principal Research Scientist at Charnwood Discovery. His career has been split between organic chemistry and peptide synthesis. It began in the School of Chemistry at the University of Nottingham in the UK, where James earned his PhD in 2015 for his work on the development of fluorine MRI probes for imaging protease activity. 

James then went on to begin his industrial career, first in peptide chemistry at Pepceuticals, followed by a move to Charnwood Discovery. He then went back into academia for a year with a Postdoc at the School of Medicine, University of Nottingham, developing Xenon MRI agents. In 2018, James returned to Charnwood Discovery where he leads a team of synthetic chemists working to meet his clients’ needs.

Cyclic Peptides Synthesis_James_Krupa
Share this post: